• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Diligent Announces Market Insights Reporting Powered by S&P Global Market Intelligence, Giving Directors and Executives Unrivaled Financial and Risk Insights

    1/15/25 9:00:00 AM ET
    $MYGN
    $YEXT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    EDP Services
    Technology
    Get the next $MYGN alert in real time by email

    New reports bring key financial insights and market comparisons to directors, CFOs, general counsel and executives, giving clarity into investor risks.

    Diligent, a leading GRC SaaS company, today announced it is collaborating with S&P Global's Market Intelligence division to launch Diligent Market Insights Reporting. Powered by S&P Capital IQ Pro data, the reports give corporate directors and executives timely, contextualized insights into global financial data and peer performance – including market sentiment, analyst consensus, peer developments and industry analysis – to stay ahead of market and investor risks. The reports are built within the Diligent One Platform, Diligent's leading GRC platform empowering more than 1 million users and 700,000 board members and leaders to make better decisions.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115272711/en/

    (Graphic: Business Wire)

    (Graphic: Business Wire)

    "Today's corporate directors are navigating an increasingly complex and fast-moving risk landscape," said Mark Davis, Board Director at Yext (NYSE:YEXT) and Myriad Genetics (NASDAQ:MYGN), former National Audit Leader of Deloitte Private and Greater Tri-state IPO Services Leader. "Staying ahead of these dynamics requires more than traditional reporting—it demands timely, contextualized insights that empower leaders to anticipate risks and seize opportunities. Boards need tools that bridge the gap between raw data and actionable insights to drive informed, strategic decisions."

    In today's fast-paced business landscape, public company boards and executives need timely and relevant financial data to make informed decisions. Diligent Market Insights Reporting integrates S&P Global Market Intelligence's unparalleled financial data with Diligent Boards to deliver industry expert designed reports of a company's market position, directly to boards and leadership. This integration allows for a more streamlined and curated delivery of data so leadership can gain clarity into investor risks.

    Key benefits of Diligent Market Insights Reporting powered by S&P Capital IQ Pro data include:

    • Access to the latest comprehensive market data including peer comparisons, stock charts, key developments, market analysis, analyst price targets, recommendations, and earnings sentiment analysis.
    • Tailored insights for corporate directors, CFOs, GCs and CEOs, delivered securely and in a familiar and consistent format, in the world's leading board portal.
    • Enhanced decision making, empowering executive leaders with the tools to deliver the right insights and context to the board, enhancing their ability to make strategic decisions.
    • Seamless integration to Diligent Boards, enabling CFOs, finance and investor relations teams to easily pull data from a single source, provide commentary on key developments and share with stakeholders.

    Through the Diligent One Platform, customers can also gain access to other board reporting integrations to streamline data collection, break down silos and surface clear insights built on reliable, up-to-date data.

    "This collaboration with S&P Global Market Intelligence underscores our commitment to delivering actionable and reliable market insights to our customers," said Brian Stafford, President and CEO of Diligent. "Market Insights Reporting will elevate how boards and executives access and utilize financial data, ensuring they are always prepared to make informed decisions that drive their organizations forward."

    "We are excited to work with Diligent on this innovative capability," said Warren Breakstone, Global Head of Data & Research at S&P Global Market Intelligence. "By integrating our financial insights with Diligent's governance technology, we are assisting boards and executives to navigate the complexities of today's financial landscape with greater confidence and clarity."

    For more information on Market Insights Reporting powered by S&P Global Market Intelligence, visit: https://www.diligent.com/lp/market-insights-reporting

    About Diligent

    Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.

    Follow Diligent on LinkedIn, X (Twitter) and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250115272711/en/

    Media Contact

    Julia Stoyanov

    Communications Director, Diligent

    +1 (604) 669-4225

    [email protected]

    Get the next $MYGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYGN
    $YEXT

    CompanyDatePrice TargetRatingAnalyst
    Yext Inc.
    $YEXT
    3/11/2026$6.00Buy → Neutral
    Roth Capital
    Yext Inc.
    $YEXT
    6/4/2025$10.00Neutral → Buy
    B. Riley Securities
    Myriad Genetics Inc.
    $MYGN
    5/21/2025$6.00Sector Outperform → Sector Perform
    Scotiabank
    Myriad Genetics Inc.
    $MYGN
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    Myriad Genetics Inc.
    $MYGN
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    Myriad Genetics Inc.
    $MYGN
    4/9/2025Buy → Neutral
    Guggenheim
    Myriad Genetics Inc.
    $MYGN
    3/12/2025$11.50 → $12.50Neutral → Overweight
    Piper Sandler
    Myriad Genetics Inc.
    $MYGN
    2/12/2025$29.00Buy
    Craig Hallum
    More analyst ratings

    $MYGN
    $YEXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Yext, Inc. Announces Preliminary Results of Modified Dutch Auction Tender Offer

    Yext, Inc. (NYSE:YEXT) ("Yext"), the leading digital presence platform for multi-location brands, today announced the preliminary results of its "modified Dutch Auction" tender offer for shares of its common stock, which expired at 5:00 p.m., New York City time, on March 18, 2026. Based on the preliminary count by Broadridge Corporate Issuer Solutions, LLC, the depositary for the tender offer (the "Depositary"), a total of 64,449,935 shares of Yext's common stock, par value $0.001 per share (each share of Yext's common stock, a "Share," and collectively, "Shares"), were properly tendered and not properly withdrawn at or below the purchase price of $5.75 per Share, including 19,257,357 Sha

    3/19/26 8:00:00 AM ET
    $YEXT
    EDP Services
    Technology

    Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

    SALT LAKE CITY, March 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer. This approval is based on final data from the PRIMA trial, where the MyChoice CDx Test determined homologous recombination deficiency (HRD) status and was used to stratify advanced ovarian cancer patients. The MyChoice CDx is the only FDA-approved companion diagnostic test in the United States to identify patie

    3/17/26 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Yext Announces Fourth Quarter and Fiscal Year 2026 Results

    Q4 Revenue of $112.0 million and FY26 Revenue of $446.6 million Q4 Net Income Per Share, basic, of $0.03 or non-GAAP Net Income Per Share of $0.15 FY26 Net Income Per Share, basic, of $0.31 or non-GAAP Net Income Per Share of $0.56 Q4 Adjusted EBITDA of $29.0 million, resulting in an Adjusted EBITDA margin of 26% FY26 Adjusted EBITDA of $107.3 million, resulting in an Adjusted EBITDA margin of 24% ARR of $444.3 million Recently launched tender offer to repurchase up to $140.0 million of common stock Yext, Inc. (NYSE:YEXT), the leading digital presence platform for multi-location brands, today announced its results for the three months ended January 31, 2026, or Yext's

    3/9/26 4:05:00 PM ET
    $YEXT
    EDP Services
    Technology

    $MYGN
    $YEXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Raha Samraat S. bought $199,844 worth of shares (40,000 units at $5.00), increasing direct ownership by 9% to 493,104 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/9/26 7:03:13 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    2/27/26 4:46:18 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Waugh Seth H. bought $216,647 worth of shares (32,600 units at $6.65), increasing direct ownership by 27% to 153,350 units (SEC Form 4)

    4 - Yext, Inc. (0001614178) (Issuer)

    9/19/24 4:56:10 PM ET
    $YEXT
    EDP Services
    Technology

    $MYGN
    $YEXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Yext downgraded by Roth Capital with a new price target

    Roth Capital downgraded Yext from Buy to Neutral and set a new price target of $6.00

    3/11/26 8:31:24 AM ET
    $YEXT
    EDP Services
    Technology

    Yext upgraded by B. Riley Securities with a new price target

    B. Riley Securities upgraded Yext from Neutral to Buy and set a new price target of $10.00

    6/4/25 7:32:01 AM ET
    $YEXT
    EDP Services
    Technology

    Myriad Genetics downgraded by Scotiabank with a new price target

    Scotiabank downgraded Myriad Genetics from Sector Outperform to Sector Perform and set a new price target of $6.00

    5/21/25 8:40:26 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    $YEXT
    SEC Filings

    View All

    Amendment: SEC Form SC TO-I/A filed by Yext Inc.

    SC TO-I/A - Yext, Inc. (0001614178) (Subject)

    3/19/26 8:11:26 AM ET
    $YEXT
    EDP Services
    Technology

    SEC Form SCHEDULE 13G filed by Yext Inc.

    SCHEDULE 13G - Yext, Inc. (0001614178) (Subject)

    3/16/26 4:45:12 PM ET
    $YEXT
    EDP Services
    Technology

    SEC Form S-8 filed by Yext Inc.

    S-8 - Yext, Inc. (0001614178) (Filer)

    3/10/26 4:10:10 PM ET
    $YEXT
    EDP Services
    Technology

    $MYGN
    $YEXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Haas Kevin Richard covered exercise/tax liability with 22,310 shares, decreasing direct ownership by 11% to 180,022 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/16/26 5:58:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Scientific Officer Muzzey Dale was granted 173,196 shares and covered exercise/tax liability with 37,799 shares, increasing direct ownership by 70% to 329,275 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/16/26 5:06:03 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief People Officer Solaiman Shereen was granted 173,196 shares and covered exercise/tax liability with 14,683 shares, increasing direct ownership by 145% to 267,801 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/16/26 5:06:09 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    $YEXT
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

    SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations. Scott Leffler, who has served as Chief Financial Officer since January 2024, will transition to a consulting role serving the CEO and the Board of D

    8/18/25 8:30:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    $YEXT
    Financials

    Live finance-specific insights

    View All

    Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

    Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth quarter 2025 gross margin was 70.0% and in-line with third quarter 2025. Fourth quarter 2025 GAAP net loss of $7.9 million, or $0.08 per share, while adjusted EPS was $0.04 per share and ad

    2/23/26 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2025. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please reg

    2/16/26 4:15:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

    SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com on Wednesday, January 14, 2026 at 5:15 pm PT (8:15 pm ET) in connection with the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference. Select Preliminary Four

    1/12/26 8:30:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    $YEXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

    SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

    11/14/24 4:16:31 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Yext Inc.

    SC 13G/A - Yext, Inc. (0001614178) (Subject)

    11/14/24 4:02:14 PM ET
    $YEXT
    EDP Services
    Technology

    SEC Form SC 13G filed by Myriad Genetics Inc.

    SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

    5/1/24 4:21:33 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care